ARTICLE | Clinical News

Glial derived neurotrophic factor: Phase II data

July 5, 2004 7:00 AM UTC

AMGN said in a double-blind Phase II trial in 34 patients, GDNF failed to meet the primary endpoint at 6 months. Patients who received daily infusions of 15 mg of GDNF into the putamen region of the b...